# Faeth Therapeutics

> Faeth Therapeutics is an Austin-based, publicly traded clinical-stage oncology company developing PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib that blocks PI3K-alpha, mTORC1 and mTORC2. Founded around cancer metabolism and precision nutrition, Faeth has narrowed its near-term bet to multi-node pathway inhibition in biomarker-selected endometrial and advanced breast cancers, backed by two enrolling trials, an FDA Fast Track designation and the capital of a 2026 reverse merger and $200 million private placement.

- **Founded:** 2019
- **Headquarters:** Austin, United States
- **Founders:** Anand Parikh (Chair, CEO & Co-Founder), Oliver Maddocks (Co-Founder & Chief Scientific Officer), Lewis Cantley (Scientific Co-Founder), Siddhartha Mukherjee (Scientific Co-Founder), Karen Vousden (Scientific Co-Founder), Scott Lowe (Scientific Co-Founder), Greg Hannon (Scientific Co-Founder), Marcus Goncalves (Scientific Co-Founder), Benjamin Hopkins (Scientific Co-Founder), Simon Knott (Scientific Co-Founder)
- **Team size:** Approximately 37 employees according to supplied company data; current public filings do not provide a directly comparable headcount.
- **Products:** PIKTOR (FTH-PIK-201), PIKTOR (FTH-PIK-101), Sapanisertib exploratory program, MetabOS, NEAAR
- **Notable:** Raised $92 million in private capital before the 2026 transaction., Completed a reverse merger with Sensei Biotherapeutics alongside a $200 million private placement in February 2026., Began trading on Nasdaq under ticker FTH in June 2026.

## Products & services

- **PIKTOR (FTH-PIK-201)** — Investigational all-oral serabelisib plus sapanisertib regimen combined with paclitaxel in an enrolling Phase 2 study for biomarker-selected advanced or recurrent endometrial cancer.
- **PIKTOR (FTH-PIK-101)** — Investigational Phase 1b/2 program combining PIKTOR with fulvestrant and/or other anticancer therapy for HR-positive, HER2-negative advanced breast cancer.
- **Sapanisertib exploratory program** — An mTORC1/2 inhibitor retained for potential future indications; current company materials describe the program as exploratory.
- **MetabOS** — A machine-learning and functional-genomics discovery platform created to identify metabolic vulnerabilities by tumor genotype, organ of origin and therapy; it informed Faeth’s earlier precision-nutrition and target-discovery work.
- **NEAAR** — A formulated non-essential amino acid restriction program previously studied with cancer therapy, including in colorectal and rectal cancer settings; it is not listed among the three programs on Faeth’s current public pipeline page.

## Achievements

- Raised $92 million in private capital before the 2026 transaction.
- Completed a reverse merger with Sensei Biotherapeutics alongside a $200 million private placement in February 2026.
- Began trading on Nasdaq under ticker FTH in June 2026.
- Dosed the first patient in the FTH-PIK-101 advanced breast cancer trial in April 2026.
- Received FDA Fast Track designation in August 2026 for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer.
- Reported a 47% overall response rate among 15 response-evaluable patients in a small investigator-initiated Phase 1b study; seven pathway-altered evaluable patients had a 71% response rate, including three complete responses across the study.
- Published preclinical multi-node inhibition work in the British Journal of Cancer in 2025.

## Latest updates

- **2026-08** — FDA granted Fast Track designation to PIKTOR plus paclitaxel for biomarker-selected advanced or recurrent endometrial cancer after specified prior treatments.
- **2026-08** — Faeth reported $186.4 million in cash, cash equivalents and marketable securities at June 30, 2026, with a $16.0 million second-quarter net loss.
- **2026-08** — The company presented pharmacokinetic/pharmacodynamic modeling used to select the PIKTOR dose in the ongoing FTH-PIK-201 trial.
- **2026-06** — The combined company changed its name to Faeth Therapeutics, Inc. and began Nasdaq trading under FTH; Anand Parikh became chair, president and CEO.
- **2026-04** — The first patient was dosed in the Phase 1b/2 FTH-PIK-101 breast cancer study.
- **2026-02** — Sensei Biotherapeutics acquired Faeth and closed a concurrent $200 million private placement.

## Links

- Website: https://www.faeththerapeutics.com/
- LinkedIn: https://www.linkedin.com/company/faeththerapeutics/
- Twitter/X: https://twitter.com/faethtx
- Instagram: https://www.instagram.com/faeththerapeutics/
- Facebook: https://www.facebook.com/faeththerapeutics/

---

Profile page: https://yespress.io/faeth-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-21